The ocular renin-angiotensin system: A therapeutic target for the treatment of ocular disease

被引:45
作者
Giese, Michael J. [1 ]
Speth, Robert C. [1 ]
机构
[1] Nova SE Univ, Dept Pharmaceut Sci, Ft Lauderdale, FL 33328 USA
基金
美国国家卫生研究院;
关键词
Eye; Ocular; Glaucoma; Retina; Renin-angiotensin system; Angiotensin II; ENDOTHELIAL GROWTH-FACTOR; II TYPE-1 RECEPTOR; OPEN-ANGLE GLAUCOMA; CONVERTING-ENZYME-INHIBITOR; ENDOTOXIN-INDUCED UVEITIS; PROLIFERATIVE DIABETIC-RETINOPATHY; RETINAL-PIGMENT EPITHELIUM; SMOOTH-MUSCLE-CELLS; OXYGEN-INDUCED RETINOPATHY; MOUSE LACRIMAL GLAND;
D O I
10.1016/j.pharmthera.2013.11.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The renin-angiotensin system (RAS) is most well-known for its role in regulation and dysregulation of blood pressure as well as fluid and electrolyte homeostasis. Due to its ability to cause cardiovascular disease, the RAS is the target of a multitude of drugs that antagonize its pathophysiological effects. While the "classical" RAS is a systemic hormonal system, there is an increasing awareness of the existence and functional significance of local RASs in a number of organs, e.g., liver, kidney, heart, lungs, reproductive organs, adipose tissue and adrenal. The eye is one of these organs where a compelling body of evidence has demonstrated the presence of a local RAS. Individual components of the RAS have been shown to be present in many structures of the eye and their potential functional significance in ocular disease states is described. Because the eye is one of the most important and complex organs in the body, this review also discusses the implications of dysregulation of the systemic RAS on the pathogenesis of ocular diseases and how pharmacological manipulation of the RAS might lead to novel or adjunctive therapies for ocular disease states. (c) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:11 / 32
页数:22
相关论文
共 247 条
[11]  
Borovic Djina, 2009, Oftalmologia, V53, P61
[12]   RENIN MESSENGER-RNA IS SYNTHESIZED LOCALLY IN RAT OCULAR-TISSUES [J].
BRANDT, CR ;
PUMFERY, AM ;
MICALES, B ;
BINDLEY, CD ;
LYONS, GE ;
SRAMEK, SJ ;
WALLOW, IHL .
CURRENT EYE RESEARCH, 1994, 13 (10) :755-763
[13]   Pharmacological management of ocular hypertension: current approaches and future prospective [J].
Bucolo, Claudio ;
Salomone, Salvatore ;
Drago, Filippo ;
Reibaldi, Michele ;
Longo, Antonio ;
Uva, Maurizio Giacinto .
CURRENT OPINION IN PHARMACOLOGY, 2013, 13 (01) :50-55
[14]   Carbon monoxide and the eye: Implications for glaucoma therapy [J].
Bucolo, Claudio ;
Drago, Filippo .
PHARMACOLOGY & THERAPEUTICS, 2011, 130 (02) :191-201
[15]   ACE inhibition salvages the visual loss caused by diabetes [J].
Bui, BV ;
Armitage, JA ;
Tolcos, M ;
Cooper, ME ;
Vingrys, AJ .
DIABETOLOGIA, 2003, 46 (03) :401-408
[16]   CIRCULATING AND TISSUE ANGIOTENSIN SYSTEMS [J].
CAMPBELL, DJ .
JOURNAL OF CLINICAL INVESTIGATION, 1987, 79 (01) :1-6
[17]  
Caspi RR, 1999, SPRINGER SEMIN IMMUN, V21, P113, DOI 10.1007/s002810050056
[18]   Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes [J].
Chaturvedi, N ;
Sjolie, AK ;
Stephenson, JM ;
Abrahamian, H ;
Keipes, M ;
Castellarin, A ;
Rogulja-Pepeonik, Z ;
Fuller, JH .
LANCET, 1998, 351 (9095) :28-31
[19]   Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials [J].
Chaturvedi, Nish ;
Porta, Massimo ;
Klein, Ronald ;
Orchard, Trevor ;
Fuller, John ;
Parving, Hans Henrik ;
Bilous, Rudy ;
Sjolie, Anne Katrin .
LANCET, 2008, 372 (9647) :1394-1402
[20]   Role of angiotensin II in retinal leukostasis in the diabetic rat [J].
Chen, Ping ;
Scicli, Gloria M. ;
Guo, Meng ;
Fenstermacher, Joseph D. ;
Dahl, David ;
Edwards, Paul A. ;
Scicli, A. Guillermo .
EXPERIMENTAL EYE RESEARCH, 2006, 83 (05) :1041-1051